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Mutations in keratin 1 were initially described in the
classical form of bullous congenital ichthyosiform
erythroderma (also known as epidermolytic hyper-
keratosis). More recently the range of phenotypes
associated with mutations in this gene has been
extended to include annular ichthyosiform erythro-
derma and mild epidermolytic palmoplantar kerato-
derma. Here we present two novel mutations in the
keratin 1 gene (KRT1): a 5¢ donor splice site muta-
tion in exon 1 (591 + 2T > A) that predicts a 22
amino acid in-frame deletion in the keratin 1 1A
domain; and an in-frame deletion in exon 7
(1376del24) that predicts a foreshortened 2B coiled-
coil domain of keratin 1. In each case these muta-
tions are associated with palmoplantar keratoderma
and mild ichthyosis, largely limited to the ¯exural
areas. These mutations appear to have a less dam-
aging effect than previously reported mis-sense
mutations sited in the helix boundary motifs. This
report extends the range of phenotypes associated
with mutations in KRT1. Key words: disorder of kerati-
nization/genetics/genodermatosis/intermediate ®laments/
mutation. J Invest Dermatol 119:966±971, 2002
T
he traditional classi®cation of palmoplantar kerato-
dermas (PPK) has been by morphologic appearance,
i.e., diffuse, focal, or punctate, and the presence or
absence of extracutaneous features (Stevens et al,
1996). Recent advances in understanding the mole-
cular basis of these disorders have facilitated a molecular-based
classi®cation (Irvine and Paller, 2002). Keratins are structural
proteins found in all epithelial cells (Lane, 1995). They are divided
into type I (K9±20) and type II (K1±8) keratins, and are normally
expressed in pairs consisting of one of each type in a tissue- and
differentiation-speci®c manner. Speci®c pairs of type I and type II
keratins form heteropolymeric 10 nm intermediate ®laments,
which serve to protect epithelial cells from physical damage
(Irvine and McLean, 1999). In the highly specialized palmoplantar
epidermis the keratin expression pattern is tightly regulated with
speci®c expression of keratins K9, K16, and K17 (Swensson et al,
1998). K1 is the putative expression partner of both K9 and K10 in
the palmoplantar epidermis and the partner of K10 in interfollicular
epidermis in nonglabrous skin. Pathogenic mutations in keratin
genes are now known to underlie a range of human epithelial
fragility disorders with the majority of mutations occurring in the
helix boundary motifs, highly conserved regions at either end of
the rod domain (Irvine and McLean, 1999). Following the ®rst
reports of mutations in the suprabasal cytokeratin K1 and its
expression partner K10 in patients with classical bullous congenital
ichthyosiform erythroderma (BCIE; also known as epidermolytic
hyperkeratosis, EHK) (Cheng et al, 1992; Chipev et al, 1992;
Rothnagel et al, 1992), a diverse range of subtly different
phenotypes has been ascribed to mutations in K1. PPK is a more
prominent feature of the BCIE patients with mutations in K1 than
those with K10 mutations (DiGiovania and Bale, 1994), possibly
because K1 is the major expression partner of K9 in palmoplantar
epidermis. K1 mutations have also been shown to underlie the
annular ichthyosis variant of BCIE (Michael et al, 1999; Sybert et al,
1999), and a mutation in K1 has been associated with none-
pidermolytic PPK in a single family (Kimonis et al, 1994). More
recently a novel splice site mutation leading to the insertion of 54
nucleotides into the K1 2B domain was shown to cause a mild
epidermolytic PPK (Hatsell et al, 2001). At the time of writing a
total of 23 different mutations have been reported in K1 (Cassidy et
al, 2002). Here we report two novel mutations in K1, each
associated with a well-demarcated diffuse PPK and very limited
involvement elsewhere. This report extends the knowledge of
genotype±phenotype correlation in K1 disorders.
MATERIALS AND METHODS
K1exon 7 mutation detection and con®rmation Buccal cell DNA
was used to amplify a 390 bp fragment of the KRT1 gene encompassing
all of exon 7 (collected and prepared using the GeneDx Buccal Cell
collection kit as previously described; Richards et al, 1993).
Ampli®cation consisted of one cycle at 95°C, 15 min, 37 cycles of 94°C,
30 s, 62°C, 60 s, 72°C, 90 s, and a ®nal cycle at 72°C, 5 min. Reactions
contained 1 ml buccal DNA, 200 nM each primers K1ex7F and K1ex7R
(Table I), 0.2 nM deoxyribonucleoside triphosphate, 0.15 U HotStart
Taq polymerase and 1 3 polymerase chain reaction (PCR) buffer
(Qiagen, Valencia, CA). The ampli®ed fragments were gel-puri®ed
through 2% agarose (Seakem LE, BioWhittaker, North Brunswick, NJ)
and isolated using EZNA DNA column puri®cation (Omega-Bio-Tek,
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Doraville, GA). An aliquot was subjected to simultaneous bidirectional
sequencing using IRD-700 and IRD-800 dye-labeled M13
oligonucleotide primers and the Dyenamic sequencing system (AP
Biotech, Piscataway, NJ). Sequence reactions were analyzed on a LI-
COR dual-dye DNA Analyzer.
To con®rm the deletion of 24 bp from one allele of exon 7 of the
patient's KRT1 gene, the 390 bp DNA fragment was digested with the
restriction endonuclease StyI and analyzed on 3% agarose (3 : 1 Nusieve,
BioWhittaker). Only the expected pair of bands from a normal KRT1
allele was seen in control DNA (208 bp, 182 bp), whereas an additional
158 bp band was observed in DNA from the affected patient (data not
shown).
K1exon 1 5¢ donor splice site mutation detection and
con®rmation Genomic DNA from the affected families and 50
unaffected local population controls was obtained from peripheral blood
lymphocytes using the Nucleon DNA Extraction Kit (Amersham
Pharmacia Biotech, Little Chalfont, Bucks, U.K.).
Two hundred nanograms of genomic DNA was used to amplify a
723 bp fragment of the KRT1 gene, including exon 1 and the intron 1
5¢ donor splice site, using 1 mM each of primers K1e1.F and K1e1.R
(Table I), 0.25 mM of each deoxyribonucleoside triphosphate and 1 U
Taq polymerase (Promega, Madison, WI) in 1 3 NH4 PCR Buffer
(Bioline Ltd, London, U.K.) supplemented with 1.5 mM MgCl2 and 4%
dimethyl sulfoxide. Following DNA denaturation at 94°C for 5 min,
PCR was performed for 35 cycles of 94°C, 30 s; 55°C, 45 s; and 72°C,
90 s; with a ®nal 5 min extension at 72°C. PCR products were puri®ed
using QIAquick PCR puri®cation method (Qiagen, Crawley, U.K.)
prior to DNA sequencing on an automated ABI 377 DNA sequencer
(Applied Biosystems, Perkin Elmer, Foster City, CA) using an internal
primer, K1-H1 (Table I).
In this case the mutation was con®rmed by denaturing high-pressure
liquid chromatography (dHPLC). PCR with primers K1e1.F and
K1e1.R was performed using HotStart Taq polymerase (Qiagen) as
recommended by the manufacturer; otherwise conditions were as stated
above. Following PCR, DNA fragments were subjected to denaturation
at 95°C for 5 min and were renatured in 70 cycles of 95°C for 22 s
cooling by 1°C per cycle to allow heteroduplex formation. dHPLC was
carried out using the Wave System (Transgenomic, Crewe, U.K.) using
6±10 ml of each PCR product at 60°C melting temperature for the
723 bp K1e1F-R fragment sequence, as predicted with the WaveMaker
program (Transgenomic). Any sample that showed a different elution
pro®le compared with a normal KRT1 control was sequenced.
Splicing assay system In order to demonstrate the effect of the
KRT1-591 + 2T > A mutation at an mRNA level we developed an
in vitro splicing assay system based on transfection of KRT1 genomic
DNA constructs into HaCaT cells (Boukamp et al, 1988). A 1466 bp
fragment of KRT1 gene, including part of exon 1, intron 1, and exon 2,
which corresponds to H1, 1A, and part of L1 motifs of the K1 protein,
was ampli®ed from genomic DNA of the affected father in family 2.
PCR was performed using 0.5 mM K1sp1 forward primer (which
includes the initiation codon and Kozak sequence to enhance
expression), and 1 mM K1e2.R reverse primer, 0.25 mM of each
deoxyribonucleoside triphosphate and 0.5 U Taq polymerase (Promega)
in 1 3 NH4 buffer (Bioline) with 1.5 mM MgCl2 and 4% dimethyl
sulfoxide. Following DNA denaturation at 94°C for 5 min, PCR was
performed for 30 cycles of 94°C for 1 min, 59°C for 1 min 30 s, and
72°C for 2 min, with a ®nal 5 min extension at 72°C. One microliter of
the PCR product was cloned into eukaryotic expression vector pCR3.1
(Bidirectional Eukaryotic TA cloning kit, InVitrogen, Paisley, U.K.) and
clones carrying the GT wild-type and GA mutant KRT1 fragments were
selected. Wild-type and mutant plasmids were isolated using Qiagen
Plasmid Maxi Kit. The HaCaT keratinocyte cell line was transfected
with GT wild-type and GA mutant plasmids using nonliposomal
FuGENE-6 Reagent (Roche, Lewes, U.K.). mRNA from wild-type and
mutant transfected cells was extracted 24 h after transfection using
QuickPrep Micro mRNA Puri®cation Kit (Amersham-Pharmacia).
mRNA was treated with RNAse-free DNAse I (Promega) and phenol/
chloroform extracted, prior to reverse transcription with oligo(dT) and
AMV reverse transcriptase (Promega).
One microliter of each wild-type and mutant cDNA was ampli®ed by
nested reverse transcription±PCR; 0.5 mM T7.F and 1 mM K1e2.R
primers were used in the ®rst round of ampli®cation (PCR performed
for 42 cycles at 52°C annealing temperature, otherwise as stated above).
One microliter of each 1 : 500 diluted PCR product was used in a
second round of ampli®cation using 0.5 mM exon 1 internal primer
K1sp1 and 1 mM K1e2.R. PCR was performed as above for 30 cycles
and an annealing temperature of 59°C. Nested PCR products were
sequenced using primer K1sp1. PCR primers are listed in Table I.
RESULTS
Clinical description of families Two families were studied. In
family 1 a single affected child was born to unaffected parents. At
birth she was noted to have a symmetric diffuse PPK but there was
no history of skin fragility or blistering, even in the neonatal period.
Until 6 y of age, the phenotype consisted only of the PPK. When
seen at 8 y of age, diffuse PPK with some super®cial scale was
noted (Fig 1a). In addition, however, the patient showed ®ne
scaling over the lateral and anterior neck, lower back, external ears,
and axillae (Fig 1b).
The second family comprised an affected father and an affected
daughter. In each case, a mild diffuse PPK was observed at birth,
there was no history of neonatal fragility or blistering. The father,
now aged 34, had persistent mild diffuse PPK throughout life and
mild ¯exural-limited scaling. His daughter has a similarly mild
presentation, with involvement limited to the palms and soles,
popliteal fossae, and axillae (Fig 1c,d).
Identi®cation of a novel deletion mutation in exon 7 of
KRT1 in family 1 Bidirectional sequence of KRT1 exon 7
demonstrated a heterozygous in-frame deletion of 24 bp (Fig 2)
that was con®rmed by size analysis on agarose gel electrophoresis.
This mutation, designated 1376del24, causes deletion of eight
residues of the K1 protein midway between the helix 2B stutter
sequence and the beginning of the helix termination motif
(delA459-Q466).
Identi®cation of a novel splice site mutation in KRT1 and
demonstration of a 22 amino acid deletion in the H1 and 1A
domains of K1 in family 2 Sequencing of genomic DNA
revealed a heterozygous T > A substitution at base position
591 + 2, this mutation disrupts the KRT1 exon 1 donor splice
site (Fig 3). With this type of splicing defect, it is desirable to
determine the consequences at the mRNA level by reverse
transcription±PCR of keratinocyte or epidermal-derived cDNA;
however, biopsy material was not available, so in this case an in vitro
splicing assay was developed. Partial genomic DNA constructs
consisting of exons 1 and 2 of KRT1, with or without the splice
site mutation were expressed in HaCaT cells. reverse transcription±
PCR and direct sequencing of KRT1 cDNA from cells transfected
with the wild-type construct showed normal splicing of exon 1 to
exon 2 (Fig 3). In contrast, direct sequencing of mutant reverse
transcription±PCR products revealed a 66 bp deletion due to
activation of an upstream cryptic donor splice site. This deletion
results in removal of 22 amino acids from the H1 and 1A domains
of the K1 polypeptide (delV175-K196); schematically represented
in Fig 3.
Con®rmation of K1 exon 1 splice site mutation and
population screening The KRT1 mutation 591 + 2T > A
was con®rmed using the Wave Transgenomic dHPLC System.
Heteroduplexes formed by the presence of either GT or GA in the
wild-type and mutant PCR fragments, respectively, were detected
Table I.
Primer Sequence: 5¢±3¢
K1ex7F CTCACTGGAGTGGGGAGACC
K1ex7R AAGGAAGGACCAGGGGAAGAG
K1e1.F GAGGAGTGTTTAGCTCCTTCCCTT
K1e1.R CTACTGTGTTTTGACTGCACCAATC
K1-H1 ATGGTCCTGTCTGCCCTCCT
K1sp1 GCACCATGCCTGTCTGCCCTCCTGGTGG
K1e2.R CATGCTGCTTCATGATCTTAGC
T7.F TAATACGACTCACTATAGGG
PCR Primers used in this study.
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in the affected father by dHPLC (Fig 4a). Fifty DNA samples from
an unaffected local population were screened to exclude this
mutation by dHPLC. This mutation was not detected in 100 alleles
examined by this technique (examples in Fig 4b±d).
DISCUSSION
Mutations in K1 are now known to underlie a number of clinically
distinct phenotypes, including classical BCIE/EHK, cyclic ichthyo-
sis with EHK, striate PPK, diffuse nonepidermolytic PPK, and, in a
single family, ichthyosis hystrix of Curth±Macklin. All mutations in
K1 and associated phenotypes reported in peer-reviewed journals
are listed in Table II. The subclassi®cation of these phenotypes is
not consistent throughout the literature; MIM numbers and entries
can also lack clarity (McKusick, 2002). In a detailed review of 21
families with BCIE/EHK DiGiovania and Bale (1994) proposed a
classi®cation of the EHK phenotype into two broad categories
based on the presence (PS) or absence (NPS) of palm and sole
involvement. The PS group was further divided into PS-1 (largely
limited involvement to palms and soles, hyperkeratosis surrounded
by a red halo), and PS-2 (extensive involvement, with neonatal
blistering). A single case did not ®t easily into either of these
categories and was classi®ed as PS-3. The DiGiovania and Bale
classi®cation is useful and is applicable to most cases of EHK. To
some extent it is possible to predict the molecular defect from the
clinical phenotype: PS phenotypes are usually due to mutations in
KRT1, and NPS phenotypes are usually due to mutations in
KRT10. Despite this usefulness, the classi®cation has not been
widely adopted and many authors reporting mutations in K1 or
K10 do not designate patients to either group. Here we have listed
all mutations in K1 to date along with the associated clinical
phenotype and PS classi®cation where designated by the authors
(Table II). It can be seen that the great majority of severe PS-2
cases is caused by point mutations in the helix initiation or
termination motifs and that milder PS-1 cases are usually caused by
point mutations outside of these sites. More unusual mutations such
in the variable domains have been associated with distinct
phenotypes (ichthyosis hystrix of Curth±Macklin and nonepider-
molytic PPK) in single families. A single insertional mutation was
associated with a mild PS-1 phenotype (Hatsell et al, 2001).
Using the DiGiovania and Bale (1994) classi®cation our second
family would be classi®ed as PS-1. The affected member of the ®rst
family is probably best classi®ed as PS-1, although the later onset of
mild ichthyosis is unusual. We report two novel mutations, both of
which result in a deletion of part of the K1 polypeptide. Deletion
mutations have been reported in other keratin genes, including a
24 bp deletion in the 2B domain of K16 causing a very mild focal
nonepidermolytic PPK phenotype (Smith et al, 2000). In this case,
expression of normal and mutant polypeptides in cultured epithelial
cells revealed that the deleted keratin was less disruptive to the
endogenous keratin network than ``classic'' keratin mis-sense
mutations in the helix boundary motifs. It was postulated that
loss of this critical protein motif that is known to be involved in
end-to-end overlap interactions during ®lament assembly (Steinert
et al, 1993) rendered the mutant protein less capable of exerting
dominant-negative effects. A similar mechanism might explain the
milder phenotype seen in patients here with deletions at either end
of the K1 rod domain. More recently, a mild phenotype (PS-1
according to DiGiovania and Bale (1994) has been attributed to a
splice site mutation in K1 that results in the insertion of 18 amino
acids into the 2B domain (Hatsell et al, 2001) and in these families
the phenotype was again limited to the palms and soles. In this case,
it is possible that disruption of the alignment of heptad repeats
within the 2B domain impairs the assembly competence of the
mutant protein, thereby lessening dominant-negative effects.
Alternatively, the inserted sequence, which is presumably unable
to contribute to dimerization, may render mutant dimers more
susceptible to degradation. Interestingly, a splice site mutation in
K5, quite similar to the mutation in family 2 here, caused an in-
Figure 1. Clinical presentation. (a) Diffuse, ®ne PPK with some
super®cial scale and (b) mild ichthyosis in the affected child from Family
1. (c) Diffuse, well-circumscribed smooth PPK and mild, scaling limited
to ¯exures in the affected child from Family 2.
Figure 2. Identi®cation of mutation 1376del24 in KRT1.Direct sequencing of KRT1 exon 7 PCR products derived from the proband in Family
1 revealed a heterozygous deletion mutation 1376del24 which removes residues 459±466 from the K1 polypeptide in the region of the helix
termination motif.
968 TERRON-KWIATKOWSKI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
frame removal of the identical 22 amino acids in the H1 and 1A
domains of K5. This K5 mutation, however, resulted in the severe
Dowling±Meara form of epidermolysis bullosa simplex (Rugg et al,
1999) rather than a milder form of the disease analogous to the K1
phenotype observed here. Similarly, truncation of the K14
polypeptide immediately after the helix termination motif was
found to produce a severe Dowling±Meara epidermolysis bullosa
simplex phenotype (Muller et al, 1999). It should be remembered,
however, that there are more keratins expressed suprabasally and,
therefore, dilution of dominant negative effects may take place in
the upper epidermis.
In conclusion, larger deletions that completely remove a keratin
helix boundary motif might be expected to have a milder
dominant-negative effect due to loss of these critical molecular
overlap regions. Notwithstanding, the prediction of phenotype
based on genotype is highly complex in keratin disorders. The
precise nature of the mutation (mis-sense vs insertion/deletion and
the affected protein domain) and as yet unde®ned genetic and
environmental factors in the affected individual all contribute to the
observed clinical phenotype.
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Table II. Mutations reported in K1 in peer-reviewed journals
Mutation/
nucleotide
Amino
acid Domain
Neonatal
blistering Pattern of EHK Diffuse PPK MIM no. Reference
221A>T K74I V1
(ISIS box)
No Mild hyperkeratosis of
nipple and umbilicus
Mild involvement of knuckle
pads, knees and elbows
Moderate to severe,
extension along
Achilles tendon
Previously
148400,
incorporated
into 144200
Kimonis et al (1994)
464T>G V155G H1 NK Mild, truncal
sparing [PS-1]
Yes, digital
contractures
113800 Yang et al (1994)
464T>A V155D H1 Yes Mild with ¯exural
accentuation
Yes 113800 Whittock et al (2001)
482T>C L161P HI Yes Mild with ¯exural
accentuation
Yes 113800 Chipev et al (1992)
536G>A R179P H1 NK Moderate±severe,
generalized
[Designated PS-1/PS-2]
Yes 113800 Yang et al (1996)
591+2T>A delV175-
K196
H1/1A No Mild ¯exural hyperkeratosis Yes This report
556A>G S186P 1A Yes, severe Severe, generalized Yes 113800 McLean et al (1994)
563A>C N188T 1A Yes, severe Severe, generalized Yes 113800 Arin et al (1999)
563A>G N188S 1A NK Severe, generalized [PS-2] Yes, digital
contractures
113800 Yang et al (1994)
563A>G N188S 1A Yes, severe Severe, generalized Yes 113800 McLean et al (1994)
563A>G N188S 1A Yes in
patient with
generalized
disease
Nevoid BCIE/EH
Severe in patient
with germline
mutation
Yes 600648 Nomura et al (2001)
577T>C S193P 1A NK Severe, generalized [PS-2] Yes, digital
contractures
113800 Yang et al (1994)
641T>C L214P 1A NK Severe, generalized Yes 113800 Cserhalmi-Friedman
et al (2000)
1019A>T D340V L12 Yes Mild, generalized scaling
[Designated PS-1]
Yes 113800 Kremer et al (1998)
IVS6+1G>A I419ins18 2B No Mild hyperkeratosis
of knees in one individual
Yes NSN Hatsell et al (2001)
1432G>T E478D 2B Red and
scaling at
birth
Mild, diffuse ichthyosis,
¯exural accentuation
Flaccid blisters [PS-1]
Yes 113800 Yang et al (1999)
1436T>C I479T 2B Yes Severe, generalized 113800 Arin et al (2000)
1445A>G Y482C 2B Yes Severe, generalized Yes 113800 Syder et al (1994)
1468G>C E490Q 2B Yes Mainly ¯exural Yes 113800 Rothnagel et al (1992)
1376del24 del459-466 2B No Mild generalized
hyperkeratosis
Yes This report
1436T>C I479T 2B Yes Relatively mild
CI-EH
Yes NSN Sybert et al (1999)
1435A>T I479F 2B Yes Mild, ¯exural in some
family members (CI-EH)
Yes NSN Sybert et al (1999)
1435A>T I479F 2B Yes Epidermolytic hyperkeratosis
with polycyclic psoriasiform
plaques, similar to CI-EH
Yes NSN Michael et al (1999)
1628delG V543fsX613 V2 No None, limited to palms
and soles
Striate PPK NSN Whittock et al (2002)
1609-
1610delGGinsA
G537fsX613 V2 No Ichthyosis hystrix of
Curth±Macklin
Severe with
pseudoainhum
146590 Sprecher et al (2001)
CI-EH, cyclic ichthyosis with epidermolytic hyperkeratosis; NSN, no speci®c number; NK, not known from published report; PS-1/PS-2 designation as from
DiGiovania and Bale (1994). Note: Mutations in this table are classi®ed according to GenBank accession no. 006121, in some cases this means that the speci®c assignment
here is different from that reported in the original paper.
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